Article citationsMore>>

S. Kotake, Y. Nanke, M. Kawamoto, T. Yago, N. Udagawa, N. Ichikawa, T. Kobashigawa, S. Saito, S. Momohara, N. Kamatani and H. Yamanaka, “T-Cell Leukemia Translocation-Associated Gene (TCTA) Protein Is Required for Human Osteoclastogenesis,” Bone, Vol. 45, No. 4, 2009, pp. 627-639. doi:10.1016/j.bone.2009.06.019

has been cited by the following article:

• TITLE: A Novel Peptide from T-Cell Leukemia Translocation-Associated Gene (TCTA) Protein Inhibits Proliferation of a Small-Cell Lung Carcinoma

  AUTHORS: Shigeru Kotake, Toru Yago, Manabu Kawamoto, Yuki Nanke

  KEYWORDS: Osteoclast; Small-Cell Lung Carcinoma; TCTA

  JOURNAL NAME: Journal of Cancer Therapy, Vol.4 No.8A, August 23, 2013

  ABSTRACT: In 2009, we demonstrated that a peptide, which we named “Peptide A”, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited both RANKL-induced human osteoclastogenesis and pit formation of mature human osteoclasts. Here, we examined the effect of Peptide A on the cell proliferation of cell lines of small-cell lung carcinoma, breast cancer, and prostate cancer: RERF-LC-MA, MCF-7, and PC-3, respectively. Peptide A inhibited the proliferation of RERF-LC-MA, but not MCF-7 or PC-3. TCTA protein was immunohistologically detected in RERF-LC-MA and MCF-7. Thus, Peptide A may provide a novel strategy for the therapy of the patients with small-cell lung carcinoma, especially with bone metastasis. In addition, Peptide A may be useful for the treatment of various cancer patients with bone metastasis.